Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000919574-25-007115
Filing Date
2025-11-19
Accepted
2025-11-19 21:15:58
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 18087
2 d12042778_ex99-a.htm EX-99 8670
3 d12042778_ex99-b.htm EX-99 14780
  Complete submission text file 0000919574-25-007115.txt   43365
Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Subject) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-90538 | Film No.: 251500847
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201
Business Address 2828 N HARWOOD STREET SUITE 1220 DALLAS TX 75201 214-550-1822
Avidity Partners Management LP (Filed by) CIK: 0001791827 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A